Literature DB >> 15242934

Targeting CD40L: a promising therapeutic approach.

Dimitris Daoussis1, Andrew P Andonopoulos, Stamatis-Nick C Liossis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15242934      PMCID： PMC440614          DOI： 10.1128/CDLI.11.4.635-641.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  69 in total

1.  Human Th1 responses driven by IL-12 are associated with enhanced expression of CD40 ligand.

Authors:  S Hirohata
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Immune cell signaling defects in lupus: activation, anergy and death.

Authors:  G C Tsokos; S N Liossis
Journal:  Immunol Today       Date:  1999-03

3.  Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus.

Authors:  Christina G Katsiari; Stamatis-Nick C Liossis; Vassilis L Souliotis; Athanasios M Dimopoulos; Menelaos N Manoussakis; Petros P Sfikakis
Journal:  Clin Immunol       Date:  2002-04       Impact factor: 3.969

4.  Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes.

Authors:  M Harigai; M Hara; S Nakazawa; C Fukasawa; S Ohta; T Sugiura; K Inoue; S Kashiwazaki
Journal:  J Rheumatol       Date:  1999-05       Impact factor: 4.666

5.  Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera.

Authors:  R K Vakkalanka; C Woo; K A Kirou; M Koshy; D Berger; M K Crow
Journal:  Arthritis Rheum       Date:  1999-05

6.  Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens.

Authors:  M Pérez-Melgosa; D Hollenbaugh; C B Wilson
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

7.  CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation.

Authors:  Miranda M L van Rijen; Mark L Kuijf; Herold J Metselaar; Hugo W Tilanus; Gerda J Bouma; Roel A de Weger; Margreet Jonker; Jaap Kwekkeboom
Journal:  Transplantation       Date:  2002-05-27       Impact factor: 4.939

Review 8.  Immune cell signaling aberrations in human lupus.

Authors:  S N Liossis; P P Sfikakis; G C Tsokos
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

9.  Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells.

Authors:  B S Devi; S Van Noordin; T Krausz; K A Davies
Journal:  J Autoimmun       Date:  1998-10       Impact factor: 7.094

10.  The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.

Authors:  Weiqing Huang; Jayashree Sinha; Jeffrey Newman; Bhoompally Reddy; Lalbachan Budhai; Richard Furie; Akshay Vaishnaw; Anne Davidson
Journal:  Arthritis Rheum       Date:  2002-06
View more
  27 in total

1.  Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-30       Impact factor: 4.219

2.  Soluble CD40 ligand in prediction of acute severe pancreatitis.

Authors:  Jean Louis Frossard; Philippe Morel; Brenda Kwak; Catherine Pastor; Thierry Berney; Léo Buhler; Alain Von Laufen; Sandrine Demulder; François Mach
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 3.  Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus.

Authors:  Juergen Foell; Robert S Mittler
Journal:  Springer Semin Immunopathol       Date:  2006-09-02

Review 4.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

5.  Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Catherine Bonham; Cara Hrusch; Paul Nolan; Wesley Klejch; Shashi Bellam; Uday Mehta; Kiran Thakrar; Janelle Vu Pugashetti; Aliya N Husain; Steven M Montner; Christopher M Straus; Rekha Vij; Anne I Sperling; Imre Noth; Mary E Strek; Jonathan H Chung
Journal:  Am J Respir Crit Care Med       Date:  2019-03-15       Impact factor: 21.405

Review 6.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

7.  Neutralization of CD40 ligand costimulation promotes bone formation and accretion of vertebral bone mass in mice.

Authors:  Susanne Roser-Page; Tatyana Vikulina; Kanglun Yu; Meghan E McGee-Lawrence; M Neale Weitzmann
Journal:  Rheumatology (Oxford)       Date:  2018-06-01       Impact factor: 7.580

Review 8.  Stop chronic kidney disease progression: Time is approaching.

Authors:  Usama Abdel Azim Sharaf El Din; Mona Mansour Salem; Dina Ossama Abdulazim
Journal:  World J Nephrol       Date:  2016-05-06

9.  Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154.

Authors:  Ilaria Deambrosis; Sara Lamorte; Fulvia Giaretta; Lorenzo Tei; Luigi Biancone; Benedetta Bussolati; Giovanni Camussi
Journal:  J Mol Med (Berl)       Date:  2008-11-05       Impact factor: 4.599

10.  CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance.

Authors:  Chang-An Guo; Sophia Kogan; Shinya U Amano; Mengxi Wang; Sezin Dagdeviren; Randall H Friedline; Myriam Aouadi; Jason K Kim; Michael P Czech
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-12       Impact factor: 4.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.